Related Experiment Video
Updated: May 10, 2025
07:05
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
22.6K
The Effects of Botulinum Toxin A Injections on Patients with Radiogenic Lower Urinary Tract Symptoms
Anke K Jaekel1,2, Ann-Christin Brüggemann3, John Bitter2
1Department of Neuro-Urology, Clinic for Urology, University Hospital Bonn, 53127 Bonn, Germany.
Toxins
|April 25, 2025
Summary
Botulinum toxin A (BTX-A) injections effectively treat radiogenic lower urinary tract symptoms (LUTS) by improving bladder capacity and reducing urinary frequency. This therapy enhances patients' quality of life without observed side effects.
Area of Science:
- Urology
- Pharmacology
Background:
- Lower urinary tract symptoms (LUTS) affect a third of patients post-pelvic radiotherapy.
- The efficacy of Botulinum toxin A (BTX-A) injections for radiogenic LUTS is not well-established.
- BTX-A is an established therapy for neurogenic and idiopathic overactive bladder.
Purpose of the Study:
- To assess the effect of BTX-A injections on radiogenic LUTS.
- To evaluate the impact of BTX-A on patients' quality of life.
- To analyze changes in urodynamic parameters following BTX-A treatment.
Main Methods:
- Retrospective analysis of 28 patients receiving BTX-A for radiogenic LUTS.
- Evaluation of bladder diary symptoms, ICIQ-LUTSqol questionnaires, and urodynamic studies (UDS).
- Pre- and post-injection data comparison.
Main Results:
- Significant reductions in daily micturition frequency, nocturia, and pad consumption.
- Improved quality of life scores (ICIQ-LUTSqol) irrespective of gender or BTX-A dosage.
- Significant increases in maximum cystometric bladder capacity, micturition volume, and first desire to void.
Conclusions:
- Intradetrusor BTX-A injections are a safe and effective treatment for radiogenic LUTS.
- Therapy leads to improved quality of life and reduced LUTS.
- BTX-A improves key urodynamic parameters in patients with radiogenic LUTS.
Related Concept Videos
01:21Skeletal Muscle Relaxants: Adverse Effects
309
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
309
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
622
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
622
01:31Skeletal Muscle Relaxants: Therapeutic Uses
439
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
439
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
356
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
356
01:11Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
418
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
418
01:21Drugs for Treatment of Constipation-Predominant IBS
109
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
109